Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 13/20 | 0.97 |
| ▸ | MAOA | P21397 | 10/20 | 0.97 |
| ▸ | ACHE | P22303 | 3/20 | 0.97 |
| ▸ | BCHE | P06276 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HTR6 | P50406 | 1/20 | 0.97 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rasagiline SCHEMBL12787613 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2827373 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL74699 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL333333 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL29605291 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL332967 | 0.98 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL828802 | 0.97 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL316969 | 0.97 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL5449858 | 0.97 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2349557 | 0.97 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705021-A2 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cadila Healthcare Limited (IN) | 2014-03-12 | — | — | EP | claimed |
| WO-2012153349-A9 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CADILA HEALTHCARE LIMITED (IN) | 2014-02-13 | — | — | WO | claimed |
| WO-2012153349-A2 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CADILA HEALTHCARE LIMITED (IN) | 2012-11-15 | — | — | WO | claimed |
| WO-2011121607-A2 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CADILA HEALTHCARE LIMITED (IN) | 2011-10-06 | — | — | WO | claimed |
| US-8741962-B2 | Process for preparation of Rasagiline and salts thereof | USV LIMITED (IN) | 2014-06-03 | — | — | US | disclosed |
| EP-2705021-A2 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cadila Healthcare Limited (IN) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012153349-A9 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CADILA HEALTHCARE LIMITED (IN) | 2014-02-13 | — | — | WO | disclosed |
| WO-2012153349-A2 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CADILA HEALTHCARE LIMITED (IN) | 2012-11-15 | — | — | WO | disclosed |
| WO-2011121607-A2 | RASAGILINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CADILA HEALTHCARE LIMITED (IN) | 2011-10-06 | — | — | WO | disclosed |
| EP-2364967-A2 | Process for preparation of rasagiline and salts thereof | USV Limited (IN) | 2011-09-14 | — | — | EP | disclosed |
| US-20110155626-A1 | PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF | USV LIMITED (IN) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110155626-A1 | PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF | RAB27A, RAB35, RAB7A | MAOB 365/4885MAOA 343/4885ACHE 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.